Richard Mauer, MD
Ophthalmology · Waterloo, IANPI 1417939067
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.3%), consulting fees and other — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 24.8% of the total. Reporting peaked in 2021 at $7,217 and has fallen 93.9% since, to $441 in 2025. Among ophthalmology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $82.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Carl Zeiss Meditec, Inc.$2K
- Biotissue Holdings Inc.$2K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$432
- AbbVie$414
- plus $2K from 20 others
What the payments were for
- Consulting fees$2,44024%
- Travel & lodging$8168%
- Food & beverage$4,46944%
- Other$2,36423%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $2,498 |
| Carl Zeiss Meditec, Inc. | 1 | $2,364 |
| Biotissue Holdings Inc. | 8 | $1,552 |
| Alcon | 28 | $1,237 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $432 |
| AbbVie(2 entities) | 17 | $414 |
| Glaukos Corporation | 5 | $211 |
| ANI Pharmaceuticals, Inc. | 7 | $184 |
| Rxsight Inc | 4 | $174 |
| Ocular Therapeutix, Inc. | 4 | $160 |
| Rayner Intraocular Lenses Limited | 3 | $129 |
| Aerie Pharmaceuticals, Inc. | 3 | $129 |
| Ivantis, Inc | 8 | $113 |
| Bausch & Lomb Americas Inc. | 4 | $113 |
| Sight Sciences, Inc. | 5 | $88 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| Harrow Eye, LLC | 1 | $37 |
| NEW World Medical,inc. | 1 | $34 |
| Merz North America, Inc. | 1 | $26 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Dompe US, Inc. | 1 | $23 |
| Mauna Kea Technologies, Inc. | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Alimera Sciences, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,327
- AmnioGraft$1,327
- Wavelight Refractive Suite$272
- Tecnis Simplicity$249
- AcrySof IQ VIVITY IOL$145
- Clareon$119
- TRYPTYR$116
- RXSIGHT INJECTOR HANDPIECE$115
- RXSIGHT CONTACT LENS$115
- RXSIGHT INJECTOR CARTRIDGE$115
- LIGHT ADJUSTABLE LENS (LAL)$115
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$115
- LUMIGAN$110
- COMBIGAN$110
- DEXTENZA$109
How this compares
$10,089 in reported general payments places this provider in the 90th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 61 | $36,388 |
| RhopressaNetarsudil Mesylate | 44 | $29,289 |
| RestasisCyclosporine | 19 | $28,741 |
| TyrvayaVarenicline Tartrate | 18 | $15,550 |
| Brimonidine Tartrate | 97 | $8,700 |
| Prednisolone Acetate | 283 | $7,765 |
| Cyclosporine | 13 | $7,606 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $7,362 |
| Timolol Maleate | 126 | $4,868 |
| Ketorolac Tromethamine | 132 | $4,628 |
| MoxifloxacinMoxifloxacin Hcl | 190 | $4,164 |
| Latanoprost | 280 | $3,156 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $2,255 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 88 | $1,379 |
| Diclofenac Sodium | 90 | $914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $414 | $72,49199 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $129 | $29,28944 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $24 | $15,55018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 172 ophthalmology providers in Iowa.
Other ophthalmology in Waterloo
- Benjamin MasonWaterloo$3K
- Edward HuHiawatha$160K
- Michael AbramoffIowa City$158K
- Stephen RussellIowa City$137K
- Jared NielsenWest Des Moines$117K
- Matthew RauenWest Des Moines$108K
- Jason JonesSioux City$83K
- Christy BensonDes Moines$70K
- Alina DumitrescuIowa City$57K
- Keith CarterIowa City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.